Markus Hecker
Corporate Officer/Principal chez Ruprecht-Karls-Universität Heidelberg
Postes actifs de Markus Hecker
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 05/11/2009 | - |
| Directeur/Membre du Conseil | - | 05/11/2009 |
Historique de carrière de Markus Hecker
Anciens postes connus de Markus Hecker
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Directeur/Membre du Conseil | 01/08/2001 | 16/06/2010 |
| Fondateur | 05/11/2009 | 16/06/2010 | |
| University of Gottingen | Corporate Officer/Principal | 01/01/1996 | 01/01/2004 |
| University of Freiburg | Corporate Officer/Principal | - | - |
| St. Bartholomew's Hospital | Corporate Officer/Principal | - | - |
| Georgetown University | Corporate Officer/Principal | - | - |
Formation de Markus Hecker
| Universität Konstanz | Doctorate Degree |
Statistiques
Internationale
| Allemagne | 6 |
| Etats-Unis | 2 |
| Royaume-Uni | 2 |
Opérationnelle
| Corporate Officer/Principal | 5 |
| Director/Board Member | 2 |
| Founder | 1 |
Sectorielle
| Consumer Services | 6 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
| St. Bartholomew's Hospital |
- Bourse
- Insiders
- Markus Hecker
- Expérience
